Arbutus Biopharma Corporation (ABUS) Dividend History

Company News

• Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.

  Moderna's stock has been struggling since the end of the COVID-19 pandemic, with a Wall Street analyst cutting her price target and reiterating a sell recommendation. The analyst cited issues such as cost-management struggles and legal headaches, as well as a hold on a late-stage trial for a norovirus vaccine candidate.

  The Motley Fool

  Featured Companies: MRNA ROIV
• Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?

  Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  Zacks Investment Research

  Featured Companies: RARE
• Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

  Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress

  GlobeNewswire Inc.
• Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

  At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment

  GlobeNewswire Inc.
• Arbutus to Participate in Jefferies Global Healthcare Conference

  WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York:

  GlobeNewswire Inc.